Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H27ClN6O2 |
| Molecular Weight | 406.91 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(N)=C(Cl)C=C1C(=O)NCC2CCN(CCCN3C=CN=N3)CC2
InChI
InChIKey=AULLTYAISZREAX-UHFFFAOYSA-N
InChI=1S/C19H27ClN6O2/c1-28-18-12-17(21)16(20)11-15(18)19(27)22-13-14-3-8-25(9-4-14)6-2-7-26-10-5-23-24-26/h5,10-12,14H,2-4,6-9,13,21H2,1H3,(H,22,27)
DA-6886 is an antagonist of the 5-HT4 receptor, discovered by the Korean Dong-A ST Research Institute. The drug binds with high activity and selectivity to human 5-HT4 receptor splice variants, with mean pKi of 7.1, 7.5 and 7.9 for the human 5-HT4a, 5-HT4b, and 5-HT4d, respectively. DA-886 induced relaxation of the rat esophagus preparation in a 5-HT4 receptor antagonist-sensitive manner. In the normal ICR mice, oral administration of the drug at 0.4 and 2 mg/kg resulted in a marked stimulation of colonic transit. DA-6886 was investigated in phase I clinical trial for the treatment of Irritable Bowel Syndrome.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12853
Created by
admin on Sat Dec 16 11:31:18 GMT 2023 , Edited by admin on Sat Dec 16 11:31:18 GMT 2023
|
PRIMARY | |||
|
1342815-16-0
Created by
admin on Sat Dec 16 11:31:18 GMT 2023 , Edited by admin on Sat Dec 16 11:31:18 GMT 2023
|
PRIMARY | |||
|
J6388YJ4YR
Created by
admin on Sat Dec 16 11:31:18 GMT 2023 , Edited by admin on Sat Dec 16 11:31:18 GMT 2023
|
PRIMARY | |||
|
54575171
Created by
admin on Sat Dec 16 11:31:18 GMT 2023 , Edited by admin on Sat Dec 16 11:31:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
